Advancing Therapy for Chronic Lymphocytic Leukemia - The Role of Rituximab

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 2, 2004, Pages 22-26

  Hillmen, Peter ^a  

^a PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE; MONOCLONAL ANTIBODY; RITUXIMAB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 1542513763     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.006     Document Type: Conference Paper

References (34)

1. Catovsky D, Fooks J, Richard S: Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72:141-149, 1989
2. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057, 1995
3. Rai KR: Chronic lymphocytic leukemia in the elderly population. Clin Geriatr Med 13:245-249, 1997
4. Zwiebel JA, Cheson BD: Chronic lymphocytic leukemia: Staging and prognostic factors. Semin Oncol 25:42-59, 1998
5. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
6. Rawstron AC, Kennedy B, Evans PA, et al: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001
7. Bosch F, Ferrer A, Lopez-Guillermo A, et al: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984, 2002
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
9. Nguyen DT, Amess JA, Doughty H, et al: 1DEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62:76-82, 1999
10. Winkler U, Jensen M, Manzke O, et al: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, 1DEC-C2B8). Blood 94:2217-2224, 1999
11. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase 11 study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
12. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001
13. Itälä M, Geisler CH, Kimby E, et al: Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur J Haematol 69:129-134, 2002
14. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003
15. Golay J, Lazzari M, Facchinetti V, et al: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98:3383-3389, 2001
16. Perz J, Topaly J, Fruehauf S, et al: Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43:149-151, 2002
17. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101: 2507-2513, 2003
18. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001
19. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
20. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
21. Czuczman MS, Fallon A, Mohr A, et al: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29:36-40, 2002 (suppl 2)
22. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
23. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20:2961-2966, 2000
24. Schulz H, Klein SK, Rehwald U, et al: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100:3115-3120, 2002
25. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent verses sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
26. Keating MJ, Manshouri T, O'Brien S, et al: A high proportion of true complete remission can be obtained with fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 22:569, 2003 (abstr)
27. Wierda W, Garcia-Manero G, O'Brien S, et al: Molecular remissions in patients with relapsed or refractory CLL treated with combined fludarabine, cyclophosphamide, and rituximab. Proc Am Soc Clin Oncol 22:581, 2003 (abstr)
28. Garcia Manero G, O'Brien S, Cortes J, et al: Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 98:633a, 2001 (abstr)
29. Lamanna N, Weiss MA, Maslak PG, et al: Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 22:580, 2003 (abstr)
30. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
31. Faderl S, Thomas DA, O'Brien S, et al: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415, 2003
32. Weiss MA, Lamanna N, Maslak PG, et al: Pentostatin, cyclophosphamide and rituximab (PCR therapy): A new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 22:580, 2003 (abstr)
33. Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). Blood 98:363a, 2001 (abstr)
34. Thomas DA, O'Brien S, Giles FJ, et al: Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98:364a, 2001 (abstr)